# A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

> **NCT05224609** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 21 (actual)

## Conditions studied

- Moderate Hepatic Impairment
- Severe Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT05224609
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-08-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05224609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05224609, "A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05224609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*